The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Paladin Labs

Monday Biotech Deal Review: December 6, 2010

Welcome to your Monday Biotech Deal Review.  There was some activity with Angiotech last week, with extension agreements being executed extending certain deadlines dealing with Angiotech’s proposed recapitalization as well as a preliminary loss in court against Rex Medical L.P.  Read on to learn more, as well as your usual assortment of biotech news.  Read more of this post

Monday Deal Review: November 1, 2010

Welcome to the Monday Deal Review for November 1, 2010.  This week’s review contains the news of a possible recapitalization of Angiotech, following its deferral of interest payments on 7.75% Senior Subordinated Notes due October 1, 2010.  Read on to learn more, as well as other happenings from last week’s biotech scene. Read more of this post

Monday Biotech Deal Review: October 18, 2010

Despite the short week, it was a busy one in the Canadian biotech sector. Read on to learn about the Labopharm / Paladin licensing deal, Ondine’s new facelift (and 15:1 equity liposuction), and various other biotech updates and news. 

Read more of this post

Monday Biotech Deal Review: April 12, 2010

This week deals are back in full force, despite the fact that Tengion’s IPO was less popular than expected and Neovacs scaled back its planned IPO.  Highlights include Patheon raising $280 million from its note placement, Verio Therapeutics getting phagocytosed by Fate (but remaining in Ottawa) and Lorus Therapeutics’ F-1 filing for a $17.5 million unit offering. Read more of this post

Monday Biotech Deal Review: March 22, 2010

Bought deals are all the rage this week, with BioExx and Osta Biotechnologies both heading in that direction.  Also, everywhere we look, warrants are being exercised and debentures are being converted. We even noted the green shoots of a new Canadian listed biotech company poking through the ground via a CPC transaction.  Is there a Spring thaw in Canada’s biotech capital markets?  Read more of this post

Monday Biotech Deal Review: March 8, 2010

A busy week in Canadian deals, with Paladin Labs in a global transaction with SpePharm; M&A activity from therapeutics and consulting companies; the last of the SIFT/SR&ED deals; over $20 million of new offerings from BioSign, Bradmer and YM; government funding for Medicago and Isotechnika; a new standby equity deal from Yorkville for Allon; and the closing of the first deal of the rest of BioMS’ new life. Read more of this post

Monday Biotech Deal Review: March 1, 2010

This week saw a lot of offerings move forward, in the shadow of Anthera’s shrunken and postponed IPO, but the news wasn’t all good in Canada either. ConjuChem filed for restructuring, and other companies are still holding on by their teeth. See who’s who after the jump

Monday Biotech Deal Review: February 22, 2010

There was a lot of follow-up among Canadian biotech deals this week: letters of intent turning into definitive agreements, merged companies turning to consolidation, bids launched on schedule and wrapped up; as well as an average crop of new M&Eh and securities.  Start things off with an interesting (cross-border!) twist to the SIFT/SR&ED deals we’ve seen after the jump…

Monday Biotech Deal Review: October 4, 2009

B&W_BigNickelRead on for all the details of QLT’s sale of its U.S. subsidiary, as well as more M&A and a series of securities deals from Canadian companies this week after the jump…

NRC-IRAP Is On A Roll: 7 Bio Investments in 7 Weeks

NRC-IRAP LogoNRC-IRAP,* which got $170 million in Canadian stimulus money, has been deploying funds quite rapidly and has included a significant number of biotechs in its largesse.  I found these from July and August:

Am I missing others?  Let us know in the comments.

Oh, and speaking of government money, hopefully you’ve started following the Twitter stream @crossborderbio and you saw this announcement earlier today about EDC and Brookfield’s $1 billion fund for DIP lending.

* National Research Council of Canada Industrial Research Assistance Program.  Stick to the abbreviation.

Bookmark and Share

Monday Deal Review: August 17, 2009

B&W_BigNickelIn addition to the highlights already noted — Enobia’s $50 million r0und, and the LOM – BioQuest joint venture — there was plenty of other Canadian deal activity this week.  Check it out after the jump…

Monday Deal Review: June 22, 2009

B&W_BigNickelA whole gaggle of securities deals, a cluster of licenses and a flock of M&A all migrate back to Canada for summer in this week’s Monday Deal Review.  Plus, a deal that may improve the medical isotope shortage.   after the jump…

Monday Deal Review: May 11, 2009

bignickel1Check out the latest Patheon-JLL developments, a licensing deal that looks like a subcontracting arrangement, a plan of arrangement M&A that looks like a license, and the rest of the Canadian deal info from this past week after the jump…

Follow

Get every new post delivered to your Inbox.

Join 129 other followers